ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0254

LLDAS (Low Lupus Disease Activity State) and Remission Prevent Damage Accrual in Systemic Lupus Erythematosus (SLE) Patients in a Primarily Mestizo Cohort

Manuel Ugarte-Gil1, Rocío V. Gamboa-Cárdenas2, Cristina Reátegui-Sokolova3, Victor Pimentel-Quiroz4, Mariela Medina2, Claudia Elera-Fitzcarrald4, Francisco Zevallos2, César A. Pastor-Asurza5, Jennifer Lofland6, Federico Zazzetti7, Chetan Karyekar8, Graciela Alarcón9 and Risto Perich-Campos5, 1Department of Rheumatology, Hospital Nacional Guillermo Almenara Irigoyen. EsSalud; Universidad Científica del Sur, Lima, Peru, 2Department of Rheumatology. Hospital Nacional Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 3Hospital Guillermo Almenara Irigoyen; Universidad San Ignacio de Loyola, Lima, Peru, 4Department of Rheumatology. Hospital Nacional Guillermo Almenara Irigoyen. EsSalud; Universidad Científica del Sur, Lima, Peru, 5Department of Rheumatology. Hospital Nacional Guillermo Almenara Irigoyen. EsSalud; Universidad Nacional Mayor de San Marcos, Lima, Peru, 6Global Commercial Strategic Organisation, Johnson and Johnson, Horsham, PA, 7Janssen Scientific Affairs, LLC, Buenos Aires, Argentina, 8Janssen Global Services, LLC, Horsham, PA, 9Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, The University of Alabama at Birmingham; Department of Medicine, School of Medicine; Universidad Peruana Cayetano, Heredia, Alabama

Meeting: ACR Convergence 2020

Keywords: Disease Activity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Session Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: LLDAS and remission have been proposed as treatment goals for SLE patients. However, their impact on damage prevention in patients from Latin America has been scarcely evaluated. The aim of this study was to determine if achieving LLDAS or remission prevents the occurrence of damage accrual.

Methods: SLE patients from a single center cohort with at least two visits were included. Visits were performed every six months. Remission was defined as a SLEDAI-2k (excluding serology) =0, physician global assessment (PGA)< 0.5, prednisone daily dose≤5 mg/d and immunosuppressive drugs on maintenance dose. LLDAS was defined as a SLEDAI-2k≤4 with no activity in major organ systems, with no new features of lupus disease activity compared to the previous assessment, PGA≤1.0, prednisone daily dose≤7.5 mg/d and immunosuppressive drugs on maintenance dose. Damage accrual was ascertained with the SLICC/ACR damage index (SDI). Univariable and multivariable interval-censored survival regression models were used. Two models were done: 1. Remission vs Not on remission; 2. LLDAS/Remission vs Active.  Possible confounders included in the multivariable analyses were gender, age at diagnosis, socioeconomic status, educational level, disease duration, antimalarial use and SDI. Confounders were determined at the same visit than disease activity state but the SDI was assessed at the subsequent visit.

Results: Two hundred and eighty-one patients were included, 260 (92.5%) were female, median age at diagnosis was 34.4 (25th-75th percentile: 27.1-42.4) and a median disease duration at baseline was 7.9 (25th-75th percentile: 3.9-12.8) years. Patients had median of 5 (25th-75th percentile: 2-6) visits and a median follow-up of 3.0 (25th-75th percentile: 1.8-3.5) years. Eighty-three patients (29.5%) increased their SDI during the follow-up. Based on remission, 580 visits (54.6%) were categorized as being on remission, 482 (45.4%) as not on remission. Based on LLDAS, 726 (68.4%) as being on LLDAS and 336 (31.6%) as active. In the analyses of remission, in the multivariable model, being on remission predicted a lower probability of damage (HR=0.586; 95%CI: 0.368-0.933; p=0.024). In the analyses of LLDAS, in the multivariable model, being on LLDAS predicted a lower damage (HR=0.590; 95%CI: 0.358-0.972; p=0.038). These analyses are depicted in Table 1.

Conclusion: LLDAS and Remission predicted less damage accrual. Although Remission is the desirable endpoint on the treatment of lupus, LLDAS also exerts some protective effect and thus could be an alternative endpoint in the management of these patients.

Table 1: Impact of disease activity states on damage accrual. Multivariable models.


Disclosure: M. Ugarte-Gil, Janssen, 2, Pfizer, 2; R. Gamboa-Cárdenas, None; C. Reátegui-Sokolova, Janssen, 2; V. Pimentel-Quiroz, Janssen, 2; M. Medina, None; C. Elera-Fitzcarrald, None; F. Zevallos, None; C. Pastor-Asurza, None; J. Lofland, Janssen, 3; F. Zazzetti, Janssen, 3; C. Karyekar, Janssen Global Services, LLC, 3, Johnson & Johnson, 1, Janssen, 5; G. Alarcón, None; R. Perich-Campos, None.

To cite this abstract in AMA style:

Ugarte-Gil M, Gamboa-Cárdenas R, Reátegui-Sokolova C, Pimentel-Quiroz V, Medina M, Elera-Fitzcarrald C, Zevallos F, Pastor-Asurza C, Lofland J, Zazzetti F, Karyekar C, Alarcón G, Perich-Campos R. LLDAS (Low Lupus Disease Activity State) and Remission Prevent Damage Accrual in Systemic Lupus Erythematosus (SLE) Patients in a Primarily Mestizo Cohort [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/lldas-low-lupus-disease-activity-state-and-remission-prevent-damage-accrual-in-systemic-lupus-erythematosus-sle-patients-in-a-primarily-mestizo-cohort/. Accessed May 29, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lldas-low-lupus-disease-activity-state-and-remission-prevent-damage-accrual-in-systemic-lupus-erythematosus-sle-patients-in-a-primarily-mestizo-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences